Allied Minds

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Allied Minds forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming the early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit.
Type
Public
HQ
Boston, US
Founded
2006
Size (employees)
359 (est)+21%
Allied Minds was founded in 2006 and is headquartered in Boston, US

Allied Minds Office Locations

Allied Minds has an office in Boston
Boston, US (HQ)
3201 33 Arch St

Allied Minds Data and Metrics

Allied Minds Financial Metrics

GBP

Market capitalization (21-Sep-2017)

368.2 m

Closing share price (21-Sep-2017)

1.6
Allied Minds's current market capitalization is £368.2 m.
Show all financial metrics

Allied Minds Market Value History

Traffic Overview of Allied Minds

Allied Minds Online and Social Media Presence

Allied Minds News and Updates

Woodford-backed Allied Minds lifted by strategy review

Shares in Allied Minds, the Neil Woodford backed innovation group, have been buoyed by news it is reviewing its investment strategy. It comes after the US-based London-listed firm ditched seven of its subsidiaries in a multi-million pound writedown last month. The FTSE 250 firm today said it i…

More bad news for Neil Woodford-backed US biotech company

A US biotech company backed by Neil Woodford has warned it may not survive without more cash. Woodford’s $180m (£140m) investment in Northwest Biotherapeutics has been plagued by bad news for more than a year. Shares in the company, a new brain cancer treatment developer, plummeted in the mont…

Number of business turnarounds falls in Europe

Restructuring deal activity in Europe fell by a third over the last three months, in a trend that contrasted with a spike in US distressed transactions over the same period. Some $33bn (£25.8bn) of deals were completed in Europe in 2017, 29 per cent lower than the same period last year. More than…

Woodford-backed Allied Minds dives on restructuring writedown costs

Shares in the Neil-Woodford-backed tech innovation group Allied Minds have dived as much as 18 per cent at the open after announcing a restructuring that is expected to result in $146.6m ($118m) of writedown costs. Seven of the FTSE 250-listed US company's subsidiaries will be dropped, via a sale…

Revealed: The highest and lowest chief exec pay ratios on the FTSE 350

With AGM season around the corner, and remuneration set to be a top issue for investors, chief executive pay ratios could again be about to come under the microscope. And while the certain retailers could feel the heat, a number of City firms should be able to rest easy. An influential shareho…

Term Sheet — Monday, November 28

On deals and dealmakers.
Show more

Allied Minds Company Life and Culture

You may also be interested in